PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,314 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $77.93, for a total transaction of $180,330.02. Following the transaction, the vice president owned 111,312 shares of the company’s stock, valued at approximately $8,674,544.16. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total value of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total value of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total value of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.99, for a total value of $213,683.88.

PTC Therapeutics Trading Up 0.1%

NASDAQ PTCT traded up $0.06 during trading on Monday, hitting $77.59. 2,631,928 shares of the company’s stock were exchanged, compared to its average volume of 1,795,906. The company has a market cap of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. PTC Therapeutics, Inc. has a fifty-two week low of $35.95 and a fifty-two week high of $87.50. The stock’s 50 day moving average price is $76.61 and its two-hundred day moving average price is $62.91.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.39) EPS. Analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

Institutional Trading of PTC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC bought a new position in PTC Therapeutics during the 1st quarter worth approximately $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after buying an additional 18,504 shares during the last quarter. Intech Investment Management LLC lifted its holdings in PTC Therapeutics by 62.8% in the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after buying an additional 15,167 shares during the period. Acadian Asset Management LLC lifted its holdings in PTC Therapeutics by 6.1% in the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after buying an additional 2,140 shares during the period. Finally, Strs Ohio bought a new stake in PTC Therapeutics during the first quarter valued at $438,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Barclays increased their price target on PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Jefferies Financial Group upped their target price on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Morgan Stanley restated an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a report on Thursday. Finally, Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.